Shopping Cart
Remove All
Your shopping cart is currently empty
BSJ-5-63
Copy Product Info
😃Good
Catalog No. T88693Cas No. 2519823-37-9
BSJ-5-63 is an effective degrader of CDK12, CDK7, and CDK9. It reduces the protein expression of CDK12, CDK7, CDK9, RNAPII, and Cyclin K, and also decreases the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 exhibits anticancer activity and holds potential for prostate cancer research.
BSJ-5-63
Copy Product Info😃Good
Catalog No. T88693Cas No. 2519823-37-9
BSJ-5-63 is an effective degrader of CDK12, CDK7, and CDK9. It reduces the protein expression of CDK12, CDK7, CDK9, RNAPII, and Cyclin K, and also decreases the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 exhibits anticancer activity and holds potential for prostate cancer research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | BSJ-5-63 is an effective degrader of CDK12, CDK7, and CDK9. It reduces the protein expression of CDK12, CDK7, CDK9, RNAPII, and Cyclin K, and also decreases the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 exhibits anticancer activity and holds potential for prostate cancer research. |
| In vitro | BSJ-5-63, administered at concentrations ranging from 0-1000 nM for 8 hours, dose-dependently reduces the protein expression of CDK12, CDK7, CDK9, RNAPII, and Cyclin K. Additionally, at the same concentrations but over periods of 8, 16, and 24 hours, BSJ-5-63 exhibits both dose- and time-dependent decreases in the mRNA expression of BRCA1 and BRCA2. |
| In vivo | BSJ-5-63, administered intraperitoneally at a dosage of 50 mg/kg daily over a span of 12 days, exhibited anticancer activity in a model using male ICR-SCID mice aged 4-5 weeks and implanted with 22Rv1 cells. This regimen not only significantly curtailed the growth and weight of the 22Rv1 tumors but also markedly increased apoptotic cell counts. Additionally, it resulted in an approximate 10% weight loss in the treated mice. |
| Molecular Weight | 1020.78 |
| Formula | C52H74ClN9O6S2 |
| Cas No. | 2519823-37-9 |
| Smiles | C([C@@H](NC(CCCCCCCCCCN1C[C@H](NC=2N=C(NC3=C(S(C(C)C)(=O)=O)C=CC=C3)C(Cl)=CN2)CCC1)=O)[C@](C)(C)C)(=O)N4[C@H](C(N[C@@H](C)C5=CC=C(C=C5)C=6SC=NC6C)=O)C[C@@H](O)C4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy BSJ-5-63 | purchase BSJ-5-63 | BSJ-5-63 cost | order BSJ-5-63 | BSJ-5-63 chemical structure | BSJ-5-63 in vivo | BSJ-5-63 in vitro | BSJ-5-63 formula | BSJ-5-63 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.